Bank of America’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $25M | Buy |
256,833
+68,054
| +36% | +$5.94M | ﹤0.01% | 2286 |
|
|
2026
Q1 | $15.8M | Sell |
188,779
-276,759
| -59% | -$16M | ﹤0.01% | 2582 |
|
|
2025
Q4 | $19.2M | Buy |
465,538
+285,513
| +159% | +$11.1M | ﹤0.01% | 2337 |
|
|
2025
Q3 | $7.08M | Buy |
180,025
+14,900
| +9% | +$381K | ﹤0.01% | 3661 |
|
|
2025
Q2 | $3.08M | Buy |
165,125
+71,838
| +77% | +$1.35M | ﹤0.01% | 4367 |
|
|
2025
Q1 | $1.69M | Buy |
93,287
+15,114
| +19% | +$333K | ﹤0.01% | 4809 |
|
|
2024
Q4 | $1.7M | Sell |
78,173
-9,858
| -11% | -$253K | ﹤0.01% | 4588 |
|
|
2024
Q3 | $2.41M | Buy |
88,031
+69,657
| +379% | +$1.94M | ﹤0.01% | 4420 |
|
|
2024
Q2 | $476K | Buy |
18,374
+2,879
| +19% | +$69.2K | ﹤0.01% | 5375 |
|
|
2024
Q1 | $465K | Buy |
15,495
+11,366
| +275% | +$247K | ﹤0.01% | 5399 |
|
|
2023
Q4 | $42.9K | Buy |
4,129
+4,007
| +3,284% | +$44.3K | ﹤0.01% | 6645 |
|
|
2023
Q3 | $1.67K | Sell |
122
-1,623
| -93% | -$20.4K | ﹤0.01% | 7174 |
|
|
2023
Q2 | $21.2K | Sell |
1,745
-19
| -1% | -$216 | ﹤0.01% | 6693 |
|
|
2023
Q1 | $22.4K | Buy |
1,764
+1,324
| +301% | +$14.7K | ﹤0.01% | 6735 |
|
|
2022
Q4 | $2.78K | Buy |
440
+429
| +3,900% | +$7.59K | ﹤0.01% | 7171 |
|
|
2022
Q3 | $0 | Buy |
11
+9
| +450% | +$246 | ﹤0.01% | 7914 |
|
|
2022
Q2 | $0 | Sell |
2
-503
| -100% | -$12.4K | ﹤0.01% | 8090 |
|
|
2022
Q1 | $23K | Sell |
505
-2,598
| -84% | -$142K | ﹤0.01% | 7470 |
|
|
2021
Q4 | $220K | Buy |
3,103
+689
| +29% | +$69.3K | ﹤0.01% | 6449 |
|
|
2021
Q3 | $281K | Buy |
2,414
+1,696
| +236% | +$198K | ﹤0.01% | 6056 |
|
|
2021
Q2 | $113K | Sell |
718
-6,071
| -89% | -$1.12M | ﹤0.01% | 6451 |
|
|
2021
Q1 | $1.29M | Buy |
6,789
+5,744
| +550% | +$967K | ﹤0.01% | 4619 |
|
|
2020
Q4 | $131K | Sell |
1,045
-1,714
| -62% | -$194K | ﹤0.01% | 5845 |
|
|
2020
Q3 | $300K | Buy |
2,759
+1,663
| +152% | +$197K | ﹤0.01% | 5052 |
|
|
2020
Q2 | $132K | Sell |
1,096
-322
| -23% | -$45.4K | ﹤0.01% | 5523 |
|
|
2020
Q1 | $142K | Buy |
1,418
+555
| +64% | +$103K | ﹤0.01% | 5305 |
|
|
2019
Q4 | $209K | Sell |
863
-134
| -13% | -$25K | ﹤0.01% | 5610 |
|
|
2019
Q3 | $163K | Buy |
997
+142
| +17% | +$27K | ﹤0.01% | 5782 |
|
|
2019
Q2 | $201K | Buy |
855
+112
| +15% | +$27.7K | ﹤0.01% | 5629 |
|
|
2019
Q1 | $196K | Buy |
743
+187
| +34% | +$32.3K | ﹤0.01% | 5534 |
|
|
2018
Q4 | $51K | Buy |
556
+504
| +969% | +$68.7K | ﹤0.01% | 6209 |
|
|
2018
Q3 | $10K | Buy |
+52
| New | +$10.9K | ﹤0.01% | 6673 |
|
Other funds holding DNTH
FFM
APM
OCA
Bank of America's DNTH Position: Q2 2026 in Review
Bank of America increased its Dianthus Therapeutics (DNTH) stake by 36% in Q2 2026, buying an estimated $5.94M and bringing the position to 256,833 shares worth $25M. The position accounts for ﹤0.01% of the portfolio, ranked #2286.
Bank of America first reported a position in DNTH in Q3 2018 and has held it in 32 quarters since. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.
- Bank of America held 256,833 shares of Dianthus Therapeutics worth $25M as of Q2 2026.
- Bank of America bought 68,054 Dianthus Therapeutics shares in Q2 2026, an estimated $5.94M.
- Dianthus Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #2286 holding.
- Bank of America first reported a position in Dianthus Therapeutics in Q3 2018 and has held it in 32 quarters since.
- 268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.
Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.